Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis  by Lo, Yin et al.
Journal of the Formosan Medical Association (2016) 115, 744e751Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comORIGINAL ARTICLERisk factors of ifosfamide-related
encephalopathy in adult patients with
cancer: A retrospective analysis
Yin Lo a,d, Li-Jiuan Shen a,b,c,d, Wen-Hwei Chen b,c,
Yaa-Hui Dong b, Fe-Lin Lin Wu a,b,c,*a Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan
b Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei,
Taiwan
c School of Pharmacy, College of Medicine, National Taiwan University, Taipei, TaiwanReceived 26 August 2014; received in revised form 11 July 2015; accepted 13 July 2015KEYWORDS
adverse drug
reaction;
drug toxicity;
encephalopathy;
ifosfamide;
neurotoxicity
syndromes;
risk factorsConflicts of interest: The authors
* Corresponding author. Graduate In
Taipei 100, Taiwan.
E-mail address: flwu@ntu.edu.tw
d These two authors contributed eq
http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, Formos
CC BY-NC-ND license (http://creativeBackground/Purpose: Ifosfamide, a widely used chemotherapeutic agent, has been frequently
associated with encephalopathy. A larger-scale study was conducted to identify risk factors of
ifosfamide-related encephalopathy, including hepatic function.
Methods: Adult patients who had completed at least one cycle of ifosfamide between January
2008 and December 2010 were included. Those with renal failure or liver failure were
excluded. Data were collected through chart review. Patients with encephalopathy and pa-
tients without encephalopathy were compared on age, Eastern Cooperative Oncology Group
(ECOG) performance status (PS), baseline serum creatinine (SCr) level, albumin level, white
blood cell count, liver function, brain metastasis, and dosage of ifosfamide. Chi-square test
or Fisher’s exact test, Student t test, and univariate and multivariate logistic regressions were
used for analysis.
Results: This study enrolled 337 patients. Thirty-eight patients (11%) had ifosfamide-related
encephalopathy. They had poorer ECOG PS; higher SCr level, white blood cell count, and aspar-
tate aminotransferase level; and lower serum albumin level compared with patients without
encephalopathy. Ifosfamide dosage, brain metastasis, and age were not significant risk factors.
Multivariate analysis indicated that only ECOG PS, SCr level, and albumin level contributed
significantly to the risk.
Conclusion: To date, this is the largest-scale study to have analyzed the risk factors of
ifosfamide-related encephalopathy. This study confirms that an ECOG PS of 2e4 and increased
SCr level are significant risk factors of ifosfamide-related encephalopathy, whereas increasedhave no conflicts of interest relevant to this article.
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Risk factors of ifosfamide-related encephalopathy 745albumin level decreases the risk, consistent with previous reports. Higher aspartate amino-
transferase levels have no significant impact. In contrast to previous studies, ifosfamide dosage
and brain metastasis are not significant contributing factors.
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Ifosfamide is a cytotoxic agent that is widely used in the
treatment of a wide range of malignant diseases (including
sarcomas, lymphomas, and gynecologic diseases) at
various doses and frequencies of administration. Ifosfa-
mide is an oxazaphosphorine that acts as an alkylating
agent. Approximately 50e80% of intravenous ifosfamide
is oxidized by hepatic enzymes into its active forms (4-
hydroxyifosfamide and aldofosfamide) and into other
inactive dechloroethylated and carboxy metabolites. Most
metabolites are excreted by the kidneys, with dechlor-
oethylated and carboxy metabolites accounting for 50% of
the drug excreted in urine. Hemorrhagic cystitis is a
common adverse effect of ifosfamide that is related to
one of its metabolites, acrolein. It is prevented by
administering mesna.1,2 Cases of ifosfamide-related en-
cephalopathy have often been observed in clinical prac-
tice; symptoms include neuropsychiatric conditions such
as confusion, disorientation, somnolence, agitation, hal-
lucinations, lethargy, and seizures.3e6 Symptoms usually
manifest within 48 hours of initiation, and recovery occurs
within 48e72 hours after the withdrawal of ifosfamide.
The reported incidence of ifosfamide-related encepha-
lopathy varies from 10e15% to 40%.5,7e10 Although the
exact etiology of this condition is unknown, inactive me-
tabolites of ifosfamide (including chloroacetaldehyde)
may be involved.1 Methylene blue, thiamine, and albumin
have been studied as reversing agents for this
condition.11e13
With the widespread use of ifosfamide in oncology, its
toxicity may pose a challenge to the treatment of patients
with cancer. Clinical practitioners are often unable to
identify high-risk patients prior to treatment; unexpected
development of neurologic symptoms may cause treatment
delay, treatment discontinuation, and subsequent disrup-
tion of treatment plans. Although toxicity is reversible in
most cases, severe long-term complications (including
coma and death) have been reported.7
Previously proposed risk factors include history of
cisplatin use, poor Eastern Cooperative Oncology Group
(ECOG) performance status (PS), renal dysfunction, high
cumulative dose,5,10 history of brain metastasis, and
hypoalbuminemia.7 Living in an area where hepatitis B
virus is endemic, we were interested in determining
whether liver dysfunction plays a role. To investigate the
impact of liver function on ifosfamide-related encepha-
lopathy and to further clarify risk factors within our pa-
tient population, we collected cases of adult patients who
were treated with ifosfamide in a medical center and
analyzed the pretreatment characteristics of these cases
retrospectively.Methods
The protocol used in this study was approved (approval
number 201308057RINC) by the Research Ethics Committee
of National Taiwan University Hospital (NTUH). The
requirement for informed consent was waived by the
aforementioned committee. No funding in any form was
necessary for this study.
Study population
We screened patients who were prescribed ifosfamide be-
tween January 2008 and December 2010 at the NTUH, a
2500-bed medical center with > 160 ifosfamide-treated
patients per year. This study included patients aged at least
20 years who initiated ifosfamide treatment at the NTUH
between January 2008 and December 2010 and had
completed at least one cycle of ifosfamide treatment. Pa-
tients whose treatment began at other sites or before
January 2008, those with end-stage renal disease who were
receiving renal replacement therapy, those with Child-
ePugh Stage C liver cirrhosis, and those who had completed
less than one cycle of ifosfamide treatment were excluded
from our study.
Collection of data
Medical records were reviewed. The following data were
collected for each patient: age, sex, diagnosis, concomi-
tant cytotoxic agents, ifosfamide dose per square meter
per day, ifosfamide dose per square meter per cycle, cu-
mulative ifosfamide dose per square meter, cumulative
ifosfamide dose per square meter at the onset of neurologic
symptoms, presence or absence of brain metastasis, and
presence or absence of ascites. ECOG PS, complete blood
cell count, differential blood cell count, and levels of
serum creatinine (SCr), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), total bilirubin, and
serum albumin (determined at the initiation of ifosfamide
treatment and at the onset of neurologic symptoms) were
collected.
“Patients with ifosfamide-related encephalopathy”
were defined as patients who were diagnosed as having
this condition and patients who had any of the following
neuropsychiatric symptoms that were attributed to ifosfa-
mide upon occurrence: delirium, disorientation, change
or disturbance in conscience, hallucinations, somnolence,
confusion, seizure, poor response, dizziness, agitation,
behavior or personality change, and involuntary movement.
Patients who were treated with ifosfamide during
the same time period, were not diagnosed as having
746 Y. Lo et al.encephalopathy, and were clear of any neuropsychiatric
symptoms were included in the nonencephalopathy group.
“No encephalopathy” was recorded if there were no
recorded neurologic or psychiatric symptoms upon
assessment of toxicity after ifosfamide treatment.
Data analysis
Descriptive analyses of patients included age, sex, diag-
nosis, mean dose per square meter per cycle, and mean
cumulative dose per square meter. Patients in the en-
cephalopathy group and patients in the nonencephalopathy
group were compared on age, baseline ECOG PS (0/1 or
2e4), baseline creatinine level, baseline albumin level,
baseline white blood cell (WBC) count, ifosfamide dose per
square meter per day, ifosfamide dose per square meter
per cycle, and cumulative dose per square meter. Chi-
square test was used for categorical variables (Fisher’s
exact test was used for expected values < 5). Student t test
was used for between-group comparisons of continuous
variables. Daily ifosfamide doses were grouped into four
levels: Level 1, < 2 g/m2; Level 2, 2e2.5 g/m2; Level 3,
2.6e3 g/m2; Level 4, > 3 g/m2. To compare the incidence
of encephalopathy, we formed the following subgroups:
ECOG PS (0/1 and 2e4), liver transaminase levels (AST or
ALT >100 U/L and AST and ALT 100 U/L), total bilirubin
level (> 3 mg/dL or 3 mg/dL), and the aforementioned
dose levels.
Univariate logistic regression was used to identify and
assess potential risk factors. In addition, multivariate
analysis was performed to determine independent risk
factors; covariates that were significant on univariate
regression were incorporated into multivariate analysis. All
statistics were calculated using the statistical software
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). In our
dataset, the estimated risk of encephalopathy among pa-
tients taking ifosfamide was 10%. Assuming an odds ratio of
2.0 and an R2 of 0.5 for covariates, a study population of
337 patients would have a power of  80% at an a level of
0.05.
Results
Four hundred and eighty-eight patients were prescribed
ifosfamide between January 1, 2008, and December 31,
2010. Among them, 151 were excluded for the following
reasons: age (n Z 88), previous ifosfamide therapy
(n Z 51), noncompletion of the first cycle for various rea-
sons (nZ 7), ChildePugh Stage C liver cirrhosis at the start
of therapy (n Z 3), and cancellation (and thus non-
administration) of ifosfamide treatment (n Z 2). Three
hundred and thirty-seven patients met the criteria for
analysis. Among these, 38 patients (11%) either were diag-
nosed as having ifosfamide-related encephalopathy or
developed related neurologic symptoms. Compared with
the nonencephalopathy group, the encephalopathy group
had a higher proportion of patients with higher ECOG PS
(2e4), mean creatinine level, WBC count, and AST level,
but lower mean albumin level (Table 1).
The proportion of patients with encephalopathy in the
subgroups specified previously is presented in Table 2. Therate of encephalopathy was significantly higher in patients
with poorer ECOG PS (2e4) and in patients with total bili-
rubin levels > 3 mg/dL. The rate of encephalopathy was not
significantly different among the groups given different
doses, between patients with brain metastasis and patients
without brain metastasis, or between patients with AST and
ALT levels of  100 U/L and patients with AST or ALT levels
> 100 U/L.
Univariate logistic regression was applied to significant
variables, including ECOG PS (0/1 or 2e4), total bilirubin
level ( 3 mg/dL or >3 mg/dL), albumin level, SCr level,
AST level, and WBC count. Poor ECOG PS, a total bilirubin
level > 3 mg/dL, and increased AST level, SCr level, and
WBC count increase the odds of ifosfamide-related en-
cephalopathy, whereas an increase in albumin level de-
creases the odds of adverse events. Multivariate analysis
showed that only ECOG PS, SCr level, and albumin level are
significant independent covariates (Table 3).
After other covariates had been controlled for, a patient
with an ECOG PS of 2e4 had 5.15 times as much risk of
developing encephalopathy as a patient with an ECOG PS of
0/1. A 1-mg/dL increase in SCr level increases this risk to
15.42 times, whereas a 1-g/dL increase in serum albumin
decreases the chance of encephalopathy by 67% (odds
ratio, 0.33).
Patients with ifosfamide-related encephalopathy and
their characteristics are listed in Table 4. Encephalopathy
occurred after the first cycle of treatment in 20 of 38 cases.
In these patients, baseline data and data at the onset of
symptoms were virtually the same; as a result, nearly all
comparisons between pretreatment and symptom onset
were not significantly different on various statistical tests
performed. As a group, only SCr level was significantly
higher at the onset of symptoms than at baseline (1.23 vs.
1.18, p Z 0.037, paired t test). Five patients experienced
worsening ECOG PS; however, after they were stratified by
ECOG PS (0/1 or 2e4; as with baseline data), this was no
longer statistically significant (p Z 0.25, McNemar test for
related samples). Hence, only baseline data were utilized
in our analysis.Discussion
To date, this is the largest-scale study to have analyzed
the risk factors involved in ifosfamide-related encepha-
lopathy. Most previous studies were small-scale observa-
tions (with sample size ranging from 61 patients to 237
patients) and usually evaluated each risk factor individu-
ally.5,7e9 A study by Tajino et al5 recruited 61 patients (17
cases and 44 controls) who received cisplatin and high-
dose ifosfamide (> 5 g/m2) and identified use of
cisplatin and a dose > 9 g/m2 per cycle as risk factors.
They did not include patients with SCr levels > 1.5 mg/dL
or patients with serum albumin levels < 3.5 g/dL; thus,
they could not evaluate these as possible risk factors.
Sweiss et al7 enrolled only 19 patients (8 cases and 11
controls) who received high-dose (6e25 g/m2 per cycle)
ifosfamide and indicated female sex, low total bilirubin
level, low albumin level, low hemoglobin level, and
obesity as risk factors. A study by Reiger et al8 enrolled
only 60 patients (16 cases and 44 controls) and did not
Table 1 Patient characteristics.
With encephalopathy
(n Z 38)
Without encephalopathy
(n Z 299)
All patients
(N Z 337)
p
Age (y) 52.8  12.8 48.8  13.1 49.2  13.1 0.071
Sex
Female 16 (42.1) 124 (41.5) 140 (41.5) 0.940
Male 22 (57.9) 175 (58.5) 197 (58.5)
ECOG PS
0/1 16 (42.1) 243 (81.3) 259 (76.9) <0.001a
2e4 22 (58.9) 56 (18.7) 78 (23.1)
Concurrent cisplatin 1 (2.63) 25 (8.36) 26 (7.72) 0.335
Daily dose (mg/m2) 2347.4  729.1 2329.0  1073.1 2331.1  1039.2 0.891
Dose per cycle (mg/m2) 5544.7  1595.3 5603.4  1949.4 5596.8  1910.8 0.859
Cumulative dose (g/m2) 19.02  34.02 21.70  23.55 21.39  24.90 0.533
Laboratory data
WBC count (1000 cells/mm3) 12.4  9.36 8.70  7.98 9.12  8.21 0.026b
Platelets (1000 cells/mm3) 256.9  147.1 278.7  129.0 276.2  131.1 0.335
SCr (mg/dL) 1.18  0.52 0.92  0.24 0.94  0.30 0.004b
AST (U/L) 43.2  34.7 33.1  27.6 34.2  28.6 0.039b
ALT (U/L) 39.1  34.6 33.1  38.1 33.7  37.1 0.353
Total bilirubin (mg/dL) 1.49  2.85 0.67  0.63 0.76  1.15 0.091
Albumin (g/dL) 3.72  0.77 4.18  0.50 4.14  0.54 0.002b
Data are presented as mean  SD or n (%).
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; ECOG Z Easter Cooperative Oncology Group; PS Z performance
status; SCr, serum creatinine; WBC, white blood cell.
a Statistically significant on Chi-square test. P values <0.05 are considered to be statistically significant.
b Statistically significant on Student t test. P values <0.05 are considered to be statistically significant.
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recruited 237 patients (38 cases and 199 controls) and
identified low albumin level and high SCr level as risk
factors. In contrast to previous studies, we simultaneously
assessed the effects of various risk factors on the multi-
variate logistic regression model. Because of the high
prevalence of hepatitis B virus carrier status in Taiwan
(estimated to be 15e20%, with a lower prevalence in
young adults and children),14,15 the initial aim of the study
was to explore whether hepatic abnormality is a risk factor
of ifosfamide-related encephalopathy. Although we found
that hepatic abnormality was not a risk factor, we
confirmed the involvement of other factors. The occur-
rence rate of encephalopathy among our study partici-
pants who initiated ifosfamide treatment within the study
period was 11%. The factors contributing most to the risk
of ifosfamide-related encephalopathy include poor PS and
an increase in SCr level, whereas an increase in serum al-
bumin level decreases the risk, consistent with previous
reports.7,9
In contrast to the research conducted by Tajino et al,5
which indicated that ifosfamide dosage may predispose
patients to a higher risk of encephalopathy, our study
showed that dose, dose level, and cumulative dose were
not significant contributing factors because both groups of
patients received similar dosages and cumulative doses. It
is possible that some physicians tended to prescribe rela-
tively lower doses to patients who appeared weaker;
hence, we were unable to determine whether patients
with encephalopathy received higher doses. It is also
possible that ifosfamide treatment was discontinuedprematurely among patients with encephalopathy, which
could have resulted in lower cumulative doses for patients
with encephalopathy; however, several patients devel-
oped encephalopathy late in their treatment course with
very high cumulative doses, resulting in a mean cumula-
tive dose similar to that in patients who did not develop
encephalopathy.
Similarly, age was not a significant contributor; it re-
mains unknown whether the exclusion of patients younger
than 20 years affected the results. In addition, the inci-
dence of encephalopathy among patients with brain
metastasis was not higher than that among patients without
brain metastasis, as physicians may attribute the develop-
ment of neuropsychiatric symptoms in these patients to
brain metastasis rather than to ifosfamide treatment.
Other pre-existing neurologic deficits or diseases that may
have confounded our results were not assessed in this
study.
Total bilirubin level was used as a variable because a
previous review recommended adjusting ifosfamide dosage
when the total bilirubin level was > 3 mg/dL, and we were
interested in determining the impact of the total bilirubin
level on the risk of encephalopathy.16 However, after con-
trolling for other covariates, we found that it was not an
independently significant contributor.
Additional factors reported previously were not
assessed in this study. The influence of previous cisplatin
use was not assessed because some patients did not
receive chemotherapy in our hospital but may have been
treated elsewhere; thus, their information was irretriev-
able. For similar reasons, we excluded patients who had
Table 2 Risk of encephalopathy for different groups.
Subgroups n Encephalopathy group, n (%) Odds ratio (95% CI) p
ECOG PS
0/1 259 16 (6.2) Ref <0.001a
2e4 78 22 (28.2) 5.97 (2.94e12.1)
Daily dose
Level 1 (<2 g/m2) 101 7 (6.9) NA 0.150
Level 2 (2e2.5 g/m2) 118 17 (14.4)
Level 3 (2.6e3 g/m2) 91 13 (14.3)
Level 4 (>3 g/m2) 27 1 (3.7)
Brain metastasis
Yes 30 4 (13.3) 1.24 (0.41e3.75) 0.761
No 307 34 (11.1)
Liver transaminases
AST & ALT 100 U/L 315 34 (10.8) Ref 0.292
AST or ALT >100 U/L 22 4 (18.2) 1.84 (0.59e5.75)
Total bilirubin
3 mg/dL 329 34 (10.3) Ref 0.007a
>3 mg/dL 8 4 (50.0) 8.68 (2.08e36.28)
ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; CIZ confidence interval; ECOGZ Eastern Cooperative Oncology
Group; NA Z not available; PS Z performance status; Ref Z reference.
a Statistically significant.
Table 3 Logistic regression of risk factors of
encephalopathy.
Variable Crude OR
(95% CI)
Adjusted OR
(95% CI)
ECOG PS group
0/1 Ref Ref
2e4 5.97 (2.94e12.10) 5.15 (2.35e11.28)
SCr (1 mg/dL
increase)
11.31 (3.67e34.88) 15.42 (4.36e54.59)
Albumin (1 g/dL
increase)
0.31 (0.18e0.54) 0.33 (0.17e0.65)
AST (1 U/L
increase)
1.01 (1.00e1.02) 1.00 (0.99e1.02)
WBC count
(1000 cells/
mm3 increase)
1.04 (1.01e1.07) 1.02 (0.98e1.06)
Total bilirubin
3 mg/dL Ref Ref
>3 mg/dL 8.68 (2.08e36.28) 3.82 (0.5e29.17)
AST Z aspartate aminotransferase; CI Z confidence interval;
ECOGZ Eastern Cooperative Oncology Group; ORZ odds ratio;
PS Z performance status; Ref Z reference; SCr Z serum
creatinine; WBC Z white blood cell.
748 Y. Lo et al.received ifosfamide treatment before the study period.
Similarly, electrolyte imbalance, which was reported in
earlier studies, was not assessed because of incomplete
records and large amounts of missing data. Furthermore,
we did not include patients younger than 20 years because
of local regulations and differences in the assessment of
pediatric patients.
We are aware that SCr level may not be an accurate in-
dicator of renal function. Because most of our study par-
ticipants did not perform a 24-hour urine collection,
creatinine clearance had to be retrospectively estimated,
which proved difficult because of inconsistent weight re-
cords. We decided to use SCr level as a variable because it
was measured and was more reliable.
Concurrent medications may confound the results of this
study. Concomitant opioids have been reported as a sig-
nificant risk factor.10 We assessed the impact of concomi-
tant cisplatin, which did not contribute significantly
probably because only a few patients received cisplatin
with ifosfamide. Noncytotoxic medications that may
contribute to neuropsychiatric symptoms were not assessed
because of difficulty retrieving complete information.
Future studies could be designed to include assessment of
concurrent medications that affect the central nervous
system.
The retrospective nature of this study has certain lim-
itations. First, as information was limited to medical
records, we could not assess the severity of each en-
cephalopathy case with formal grading terminology. Sec-
ond, records, descriptions of symptoms, and terminologies
may have differed among physicians, which may have
contributed to inconsistent information on neurologic
symptoms and wide confidence intervals of relative risk.
However, the significant risk factors identified in our study
were generally consistent with previous reports,5,7e9
which indicated the potentially important roles of thesefactors. Further prospective studies with predefined
criteria are necessary to precisely quantify the association
of ifosfamide-related encephalopathy with individual risk
factors. Third, baseline data may not have been obtained
immediately before treatment and may have been influ-
enced by the previous cycle of chemotherapy, leading to
erroneous assessment of organ functions.
In addition to the risk factors reported here, other fac-
tors should be assessed in future studies. Metabolism of
Table 4 Characteristics of patients with encephalopathy.
Case Age
(y)
Sex Diagnosis Concurrent
chemotherapy
Brain
metastasis
Baseline
ECOG PS
ECOG PS
at onset
Daily dose
(g/m2)
Cumulative
dose (g/m2)
Symptoms Number of
episodes
1 80 F Soft-tissue sarcoma Doxorubicin N 0 1 2.5 30.0 Delirium 1
2 75 M Head & neck cancer Etoposide N 2 3 2 28.0 Restlessness 1
3 72 F Head & neck cancer Etoposide N 0 0 2 4.0 Seizure 1
4 70 M Renal cell
carcinoma
Etoposide N 3 3 2 4.0 Change in consciousness 1
5 66 F Lung cancer Etoposide N 2 2 3 18.0 Change in consciousness 1
6 65 F Uterine sarcoma Epirubicin N 1 1 5 5.0 Poor response 1
7 64 M Lung cancer Etoposide N 2 2 3 6.0 Delirium 1
8 64 M Head & neck cancer Etoposide N 2 2 2 32.0 Involuntary movement,
dizziness
3
9 63 F Ovarian cancer Paclitaxel Y 2 2 1.5 4.5 Change in consciousness 1
10 61 M Head & neck cancer Etoposide N 1 2 3 12.0 Disorientation 1
11 60 F Breast cancer Etoposide N 1 1 3 12.0 Hallucination 1
12 58 M Head & neck cancer Etoposide N 1 1 2 4.0 Disorientation 1
13 58 M Pancreatic cancer Etoposide N 1 1 2 6.0 Delirium 1
14 57 F Uterine sarcoma Etoposide N 2 2 3 51.0 Delirium 1
15 57 M Head & neck cancer Etoposide N 1 1 1.9 3.8 Change in consciousness 1
16 55 F Endometrial cancer Etoposide Y 2 2 2 4.0 Change in consciousness 1
17 54 F Head & neck cancer Etoposide N 2 2 2 4.0 Disorientation 1
18 54 M Gastric cancer Etoposide N 3 3 3 6.0 Delirium 1
19 52 F Unknown primary Etoposide N 1 1 2 4.0 Change in consciousness 1
20 51 F Unknown primary Epirubicin N 2 2 1.65 5.0 Seizure 1
21 51 F Head & neck cancer Etoposide N 2 2 2 14.0 Confusion 2
22 50 M Lymphoma Etoposide Y 4 4 1.5 4.5 Change in consciousness 1
23 48 M Head & neck cancer Etoposide N 0 2 3 18.0 Disorientation 1
24 48 M Head & neck cancer Etoposide N 2 2 3 9.0 Hallucination 1
25 48 F Head & neck cancer Etoposide N 1 1 2 24.0 Somnolence 1
26 47 F Uterine cervical
cancer
Etoposide N 2 2 1.65 8.9 Disorientation 1
27 46 M Head & neck cancer Etoposide N 0 0 3 16.0 Agitation 1
28 46 F Breast cancer Etoposide N 3 3 2 6.0 Poor response 1
29 45 M Head & neck cancer Etoposide N 2 2 2 4.0 Change in consciousness 1
30 45 M Adrenal cancer Doxorubicin N 1 1 2 18.0 Hallucination, involuntary
movement
1
(continued on next page)
R
isk
fa
cto
rs
o
f
ifo
sfa
m
id
e
-re
la
te
d
e
n
ce
p
h
a
lo
p
a
th
y
749
T
a
b
le
4
(c
o
n
ti
n
u
e
d
)
C
a
se
A
ge
(y
)
Se
x
D
ia
gn
o
si
s
C
o
n
cu
rr
e
n
t
ch
e
m
o
th
e
ra
p
y
B
ra
in
m
e
ta
st
a
si
s
B
a
se
li
n
e
E
C
O
G
P
S
E
C
O
G
P
S
a
t
o
n
se
t
D
a
il
y
d
o
se
(g
/m
2
)
C
u
m
u
la
ti
ve
d
o
se
(g
/m
2
)
Sy
m
p
to
m
s
N
u
m
b
e
r
o
f
e
p
is
o
d
e
s
31
43
M
H
e
a
d
&
n
e
ck
ca
n
ce
r
E
to
p
o
si
d
e
N
1
1
2
4.
0
C
h
a
n
ge
in
co
n
sc
io
u
sn
e
ss
1
32
42
F
H
e
a
d
&
n
e
ck
ca
n
ce
r
E
to
p
o
si
d
e
N
3
3
3
6.
0
D
e
li
ri
u
m
1
33
42
M
O
st
e
o
sa
rc
o
m
a
E
to
p
o
si
d
e
N
1
2
3
20
4.
0
P
o
o
r
re
sp
o
n
se
,
d
iz
zi
n
e
ss
2
34
38
M
So
ft
-t
is
su
e
sa
rc
o
m
a
D
a
ca
rb
a
zi
n
e
,
d
o
ce
ta
xe
l
N
3
3
1.
5
10
.3
B
e
h
a
vi
o
r
ch
a
n
ge
1
35
32
M
G
e
rm
ce
ll
tu
m
o
r
E
to
p
o
si
d
e
,
ci
sp
la
ti
n
Y
4
4
1
20
.0
H
a
ll
u
ci
n
a
ti
o
n
1
36
31
M
Ly
m
p
h
o
m
a
G
e
m
ci
ta
b
in
e
,
vi
n
o
re
lb
in
e
N
1
1
2
32
.0
C
h
a
n
ge
in
co
n
sc
io
u
sn
e
ss
2
37
30
M
H
e
a
d
&
n
e
ck
ca
n
ce
r
E
to
p
o
si
d
e
N
2
2
3
72
.0
H
a
ll
u
ci
n
a
ti
o
n
1
38
23
M
So
ft
-t
is
su
e
sa
rc
o
m
a
E
to
p
o
si
d
e
N
4
4
3
9.
0
D
iz
zi
n
e
ss
1
E
C
O
G
Z
E
a
st
e
rn
C
o
o
p
e
ra
ti
ve
O
n
co
lo
gy
G
ro
u
p
;
F
Z
fe
m
al
e
;
M
Z
m
a
le
;
N
Z
n
o
;
P
S
Z
p
e
rf
o
rm
a
n
ce
st
a
tu
s;
Y
Z
ye
s.
750 Y. Lo et al.ifosfamide mainly involves CYP3A enzymes and possibly
CYP2B enzymes; therefore, clinically significant drug in-
teractions may be possible. Although the importance of
potential drug interactions was not assessed in this study,
concomitant use of enzyme inducers, substrates, or in-
hibitors may be clinically relevant. The contribution of CYP
2B6 inhibitors to the risk of ifosfamide-related encepha-
lopathy has already been reported.10 There have been
recent reports of ifosfamide-related central nervous
toxicity linked to the use of aprepitant, a widely used
antiemetic and CYP3A4 inhibitor.17e20 An earlier analysis
concluded that concomitant use of aprepitant increased
the risk of ifosfamide-related encephalopathy, although
the increase was not statistically significant.21 This does not
rule out the possibility of other enzyme inhibitors precipi-
tating ifosfamide-related toxicity, which warrants further
studies.
In summary, the incidence of ifosfamide-related en-
cephalopathy in our medical center was 11%. Poor PS (ECOG
PS of 2e4) and increase in SCr level are significant risk
factors contributing to this condition, whereas higher al-
bumin level significantly decreases the risk.
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